Background Hyperinflammation-induced respiratory failure is a leading cause of mortality in
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …

Background Coronavirus disease (COVID)-19 has devasted the healthcare delivery system
as well as social establishments of almost all countries of the world. However, vaccines for …

Objectives Our aim was to compare outcomes of hospitalized adults with severe COVID-19
and cytokine storm treated with tocilizumab or baricitinib. Methods A prospective …

Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized
COVID-19 patients with an inflammatory status. However, the effects of co-administering …

Introduction Many immunomodulators have been studied in clinical trials for the treatment of
coronavirus disease 2019 (COVID-19). However, data identifying the most effective and …

Background There is accumulating evidence for an overly activated immune response in
severe COVID-19, with several studies exploring the therapeutic role of immunomodulation …

Background There is accumulating evidence for an overly activated immune response
characterised by the release of pro-inflammatory cytokines in severe Covid-19. Suppression …

Background Restraining maladaptive inflammation is considered a rationale strategy to treat
severe coronavirus disease-19 (COVID-19) but available studies with selective inhibitors of …

Background Although immunomodulators have established benefit against the new
coronavirus disease (COVID-19) in general, it is uncertain whether such agents improve …

Background There is accumulating evidence for an overly activated immune response
characterised by the release of pro-inflammatory cytokines in severe Covid-19. Suppression …